Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Mallinckrodt Sets Out Four Priorities For 2019 And Foresees Specialty Generics Growth

Executive Summary

Completing the planned spin-off of its specialty generics and API business into an independent publicly-traded company is one of four priorities that Mallinckrodt has set out for 2019. Despite expecting a “relatively negative” pricing environment this year, chief executive Mark Trudeau believes the Specialty Generics division will achieve growth.

You may also be interested in...



Mallinckrodt Restructures Its Spinoff And Completes Management Team

Mallinckrodt has altered the composition of the Specialty Generics business that it plans to spin off by the end of this year, removing its Amitiza brand. The firm says it now has a “full management team in place” for the Specialty Generics unit after naming Eric Slusser as chief financial officer, to serve under president and CEO Matthew Harbaugh.

People Roundup – 26 March 2019

The latest people movements in the generics and biosimilars industries include Akorn gaining a head of quality, Polpharma naming a chief commercial officer, Pfenex appointing a new chief scientific officer, Coherus announcing a new legal head, Mallinckrodt recruiting a former Impax chief financial officer, and board changes at Krka, Advanz and Hikma.

Mallinckrodt Details Timeline And Financing For Spinning Off Generics Business

Under plans announced last December, Mallinckrodt is to spin off its specialty generics and API business; at the recent Annual J.P. Morgan Healthcare Conference, management painted a timeline to completing the project and provided details on the business’ financing and growth prospects.

Related Content

Topics

UsernamePublicRestriction

Register

GB140125

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel